PDL-1

68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers

PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

Radiomics for prEdiction of lunG cAncer biologY

PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Immune Profiling After HDR in Local Relapsed Prostate Cancer

Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC

Genetic Mutation in Epithelial Ovarian Cancer

Genetic Mutation in Recurrent Cervical Cancer

Effect of Chemotherapy on PD-L1 in NSCLC